Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash from Financing Activities (2022 - 2025)

Envoy Medical's Cash from Financing Activities history spans 4 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 56.04% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $16.2 million, up 23.49%, while the annual FY2024 figure was $20.2 million, 5.09% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $2.6 million at Envoy Medical, down from $4.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $15.7 million in Q3 2023 and bottomed at -$1.5 million in Q4 2023.
  • The 4-year median for Cash from Financing Activities is $3.6 million (2025), against an average of $4.0 million.
  • The largest annual shift saw Cash from Financing Activities crashed 172.7% in 2023 before it soared 486.31% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $2.0 million in 2022, then crashed by 172.7% to -$1.5 million in 2023, then skyrocketed by 486.31% to $5.6 million in 2024, then crashed by 53.69% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Cash from Financing Activities are $2.6 million (Q3 2025), $4.4 million (Q2 2025), and $3.6 million (Q1 2025).